About the Authors
Department of Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom
School of Biomedical and Molecular Sciences, University of Surrey, Guildford, United Kingdom
AstraZeneca AB, Mölndal, Sweden
Clinical Trials Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom
Department of Medicine, Karolinska Institute, Stockholm, Sweden
Leibniz—Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
Oxagen Limited, Abingdon, Oxfordshire, United Kingdom
Institute for Clinical Chemistry and Laboratory Medicine, University Clinics Münster, Münster, Germany
The authors have declared that no competing interests exist.
MF, FRG, JFP, PGO, RC, MLH, SR, JL, MGF, HS, AC, GO, GA, GT, RC, AH, and HW conceived and designed the experiments. MF, JFP, RC, and HW analyzed the data. MF, PGO, RC, MLH, SR, JL, MGF, HS, AC, GO, GA, GT, RC, and AH contributed reagents/materials/analysis tools. MF, FRG, JFP, and HW wrote the paper.